Nurix Therapeutics: T. Rowe Price reports 4.4% stake
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Nurix Therapeutics, Inc. was the subject of an amended Schedule 13G in which T. Rowe Price Associates, Inc. reported 4,570,774 shares, or 4.4% of the class, as beneficially owned as of September 30, 2026. The firm reported sole voting power over 4,422,815 shares and sole dispositive power over 4,570,774 shares, with no shared voting or dispositive power. It stated that the disclosure should not be construed as an admission of beneficial ownership and expressly denied such ownership; it also marked the category for ownership of 5% or less of the class.
Key Figures
Key Terms
beneficial ownership technical
sole voting power technical
sole dispositive power technical
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.